En studie for å undersøke effekten, farmakokinetikken og sikkerheten til Mitapivat hos pediatriske deltakere med transfusjonsavhengig alfa- eller beta-talassemi (α- eller β-TDT) (ENERGIZEKids-T)
En fase 3, dobbeltblind, randomisert, placebokontrollert, multikenterstudie som evaluerer effekt, farmakokinetikk og sikkerhet av Mitapivat hos pediatriske pasienter med α- eller β-transfusjonsavhengig thalassemi
The primary objective of this study is to compare the effect of mitapivat versus placebo on transfusion burden in pediatric participants with α- or β-transfusion-dependent thalassemia.
Studieoversikt
Status
Status
Forhold
Forhold
Intervensjon / Behandling
Intervensjon / Behandling
Studietype
Studietype
Registrering (Antatt)
Registrering
Fase
Fase
- Fase 3
Kontakter og plasseringer
Studiekontakt
Studiekontakt
- Navn: Agios Medical Affairs
- Telefonnummer: 833-228-8474
- E-post: medinfo@agios.com
Studiesteder
-
-
Georgia
-
Atlanta, Georgia, Forente stater, 30322
- Rekruttering
- Emory-Children's Center/ Children's Healthcare of Atlanta: Arthur M. Blank Hospital
-
-
New York
-
New York, New York, Forente stater, 10065
- Rekruttering
- Weill Cornell Medical College/ New York Presbyterian
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Forente stater, 19104-4318
- Rekruttering
- Children's Hospital of Philadelphia
-
-
Texas
-
Dallas, Texas, Forente stater, 75390
- Rekruttering
- University of Texas Southwestern Medical Center
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Written informed consent/assent from the participant (or their legally authorized representative, parent(s), or legal guardian) must be obtained before any study-related procedures are conducted and participants must be willing to comply with all study procedures for the duration of the study.
- Aged 1 to <18 years and weighing at least 7 kilograms (kg) at the time of providing informed consent/assent.
- Documented diagnosis of thalassemia (β-thalassemia with or without α-globin gene mutations, hemoglobin E (HbE)/β-thalassemia, or α-thalassemia/hemoglobin H (HbH) disease) based on Hemoglobin (Hb) electrophoresis, Hb high-performance liquid chromatography, and/or DNA analysis from the participant's medical record. If this information is not available from the participant's medical record, the test(s) can be performed by a local laboratory during the Screening Period. If a local laboratory is unable to perform the test(s), results from the comprehensive α- and β-globin genotyping performed by the study central laboratory can be used.
- Transfusion dependent, defined as 6 to 20 transfusion episodes (also referred to as "transfusion events") and a ≤6-week transfusion-free period during the 24-week period before randomization.
- If taking hydroxyurea, the hydroxyurea dose must be stable for ≥16 weeks before randomization.
- Female participants who have attained menarche must be abstinent of sexual activities that may induce pregnancy as part of their usual lifestyle, or agree to use 2 forms of contraception, 1 of which must be considered highly effective, from the time of informed consent/assent, throughout the study, and for 28 days after the last dose of study drug. The second form of contraception can include an acceptable barrier method.
Exclusion Criteria:
-
Pregnant or breastfeeding.
-
Documented history of homozygous or heterozygous hemoglobin S (HbS) or hemoglobin C (HbC).
-
Prior exposure to gene therapy or prior bone marrow or stem cell transplantation, including any prior exposure to myeloablative chemotherapy.
-
Any conditions other than thalassemia expected to affect sexual maturation.
-
Currently receiving treatment with luspatercept; the last dose must have been administered ≥36 weeks before randomization.
-
Currently receiving treatment with hematopoietic stimulating agents; the last dose must have been administered ≥36 weeks before randomization.
-
History of malignancy (active or treated) ≤5 years before providing informed consent/assent, except for nonmelanomatous skin cancer in situ, cervical carcinoma in situ, or breast carcinoma in situ.
-
History of active and/or uncontrolled cardiac or pulmonary disease or clinically relevant QT prolongation within 6 months before providing informed consent/assent.
-
Hepatobiliary disorders, including but not limited to:
- Liver disease with histopathological evidence or clinical diagnosis of cirrhosis or severe fibrosis.
- Clinically symptomatic cholelithiasis or cholecystitis (prior cholecystectomy is not exclusionary).
- History of drug-induced cholestatic hepatitis.
- Aspartate Aminotransferase (AST) >2.5*Upper Limit of Normal (ULN) (unless due to hemolysis and hepatic iron deposition) and Alanine Transaminase (ALT) >2.5*ULN (unless due to hepatic iron deposition).
-
Renal dysfunction as defined by an estimated glomerular filtration rate <60 milliliters per minute (mL/min)/1.73-meter square (m^2).
-
Nonfasting triglycerides >215 milligrams per deciliter (mg/dL) [5 millimole per liter (mmol/L)].
-
Active infection requiring systemic antimicrobial therapy at the time of providing informed consent/assent. If antimicrobial therapy is required during the Screening Period, screening procedures should not be performed while antimicrobial therapy is being administered, and the last dose of antimicrobial therapy must be administered ≥7 days before randomization.
-
Participants with known active hepatitis B or hepatitis C virus infection.
-
Participants with known human immunodeficiency virus (HIV) infection.
-
History of major surgery (including splenectomy) ≤ 6 months before providing informed consent/assent and/or a major surgical procedure planned during the study.
-
Current enrollment or past participation (within ≤12 weeks or a timeframe equivalent to 5 half-lives of the investigational study drug before administration of the first dose of study drug, whichever is longer) in any other clinical study involving an investigational treatment or device.
-
Receiving strong Cytochrome3A4/5 (CYP3A4/5) inhibitors that have not been stopped for ≥5 days or a timeframe equivalent to 5 half-lives (whichever is longer), or strong CYP3A4/5 inducers that have not been stopped for ≥4 weeks or a timeframe equivalent to 5 half-lives (whichever is longer), before randomization.
-
Receiving anabolic steroids that have not been stopped for at least 4 weeks before randomization. Testosterone replacement therapy to treat hypogonadism is allowed; the testosterone dose and preparation must be stable for ≥12 weeks before randomization.
-
Known allergy, or other contraindication, to mitapivat or its excipients (microcrystalline cellulose, croscarmellose sodium, sodium stearyl fumarate, mannitol, magnesium stearate, and the Opadry filmcoat [hypromellose, titanium dioxide, lactose monohydrate triacetin, and FD&C Blue #2]).
-
Any medical, hematological, psychological, or behavioral condition(s) or prior or current therapy that, in the opinion of the Investigator, may confer an unacceptable risk to participating in the study and/or could confound the interpretation of the study data. Also excluded are:
- Participants who are institutionalized by regulatory or court order.
- Participants with any condition(s) that could create undue influence (including but not limited to incarceration, involuntary psychiatric confinement, and financial or familial affiliation with the Investigator or Sponsor).
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Firemannsrom
Antall våpen
Våpen og intervensjoner
Deltakergruppe / ArmDeltakergruppe / Arm |
Intervensjon / BehandlingIntervensjon / Behandling |
|---|---|
|
Eksperimentell: Mitapivat
Participants will receive oral mitapivat twice daily (BID), with dose determined by age and weight, for 48 weeks during the double blind (DB) period. Enrollment is conducted sequentially by age cohort, beginning with the oldest cohort. Cohort 1: 12 to <18 years Cohort 2: 6 to <12 years Cohort 3: 1 to <6 years Participants who complete the DB period may continue receiving mitapivat in the open label extension (OLE) period for up to 144 weeks. |
Tablets or Granules
Andre navn:
|
|
Placebo komparator: Placebo
Participants will receive oral placebo matching mitapivat, administered BID, with dosing based on age and weight, for 48 weeks during the DB period. Enrollment is conducted sequentially by age cohort, beginning with the oldest cohort. Cohort 1: 12 to <18 years Cohort 2: 6 to <12 years Cohort 3: 1 to <6 years Participants who complete the DB period may transition to receive mitapivat in the OLE period for up to 144 weeks. |
Tablets or Granules
Andre navn:
Tablets or Granules |
Hva måler studien?
Primære resultatmål
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Percentage of Participants Who Achieved Transfusion Reduction Response (TRR) Through Week 48
Tidsramme: Baseline, through Week 48
|
TRR is defined as ≥50 percent (%) reduction in transfused red blood cells (RBC) volume (normalized by weight) in any consecutive 12-week period through Week 48 compared with historical RBC transfusion volume (normalized by weight) and standardized to 12 weeks. |
Baseline, through Week 48
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Prosentvis endring i transfundert RBC-volum (normalisert etter vekt) fra uke 13 til uke 48 sammenlignet med historisk transfusjonsvolum (normalisert etter vekt) og standardisert til 36 uker
Tidsramme: Baseline, uke 13 til og med uke 48
|
Baseline, uke 13 til og med uke 48
|
|
|
Endring i antall transfusjonsepisoder fra uke 13 til uke 48 sammenlignet med historisk antall transfusjonsepisoder standardisert til 36 uker
Tidsramme: Utgangspunkt, uke 13 til uke 48
|
Utgangspunkt, uke 13 til uke 48
|
|
|
Endring fra baseline i serumjern ved uke 48
Tidsramme: Utgangspunkt, uke 48
|
Utgangspunkt, uke 48
|
|
|
Endring fra utgangsverdi for total jernbindingskapasitet etter 48 uker
Tidsramme: Utgangspunkt, uke 48
|
Utgangspunkt, uke 48
|
|
|
Endring fra utgangspunkt i transferrin ved uke 48
Tidsramme: Utgangspunkt, uke 48
|
Utgangspunkt, uke 48
|
|
|
Endring fra utgangspunkt i transferrinmetning uke 48
Tidsramme: Utgangspunkt, uke 48
|
Utgangspunkt, uke 48
|
|
|
Endring fra baseline i serumferritinnivåer ved uke 48
Tidsramme: Utgangspunkt, uke 48
|
Utgangspunkt, uke 48
|
|
|
Kohort 1: Endring fra baseline i østradiol gjennom uke 48
Tidsramme: Utsgangspunkt, gjennom uke 48
|
Utsgangspunkt, gjennom uke 48
|
|
|
Kohort 1: Endring fra baseline i estron gjennom uke 48
Tidsramme: Baseline, gjennom uke 48
|
Baseline, gjennom uke 48
|
|
|
Kohort 1: Endring fra baseline i totalt testosteron gjennom uke 48
Tidsramme: Baseline, gjennom uke 48
|
Baseline, gjennom uke 48
|
|
|
Kohort 1: Endring fra baseline i fritt testosteron gjennom uke 48
Tidsramme: Baseline, gjennom uke 48
|
Baseline, gjennom uke 48
|
|
|
Kohort 1: Endring fra utgangspunkt i luteiniserende hormon gjennom uke 48
Tidsramme: Utgangspunkt, gjennom uke 48
|
Utgangspunkt, gjennom uke 48
|
|
|
Kohort 1: Endring fra baseline i seksuell modenhetsvurdering med Tanner-stadium gjennom uke 48
Tidsramme: Utgangspunkt, gjennom uke 48
|
Utgangspunkt, gjennom uke 48
|
|
|
Endring fra utgangspunkt over tid i høyde-for-alder Z-poeng, vekt-for-alder Z-poeng og kroppsmasseindeks (KMI)-for-alder Z-poeng gjennom uke 48
Tidsramme: Baseline, gjennom uke 48
|
Baseline, gjennom uke 48
|
|
|
Endring fra utgangspunkt i beinmineraltetthet (BMD) gjennom uke 48
Tidsramme: Utgangspunkt, gjennom uke 48
|
Utgangspunkt, gjennom uke 48
|
|
|
Antall deltakere med behandlingsrelaterte bivirkninger (AEs) og alvorlige bivirkninger (SAEs)
Tidsramme: Fra første dose av studiemedisin og frem til studiens slutt (opp til uke 196)
|
Fra første dose av studiemedisin og frem til studiens slutt (opp til uke 196)
|
|
|
Plasmakonsentrasjon av Mitapivat
Tidsramme: Pre-dose, og på flere tidspunkter (opptil 7 timer etter dosering) i uke 4
|
Pre-dose, og på flere tidspunkter (opptil 7 timer etter dosering) i uke 4
|
|
|
Areal under plasmakonsentrasjon–tidskurven fra tid null til siste kvantifiserbare konsentrasjon (AUC0-last) for Mitapivat
Tidsramme: Før dose, og på flere tidspunkter (opptil 7 timer etter dose) i uke 4
|
Før dose, og på flere tidspunkter (opptil 7 timer etter dose) i uke 4
|
|
|
Maksimal observert plasmakonsentrasjon (Cmax) av Mitapivat
Tidsramme: Før dosering, og på flere tidspunkt (opptil 7 timer etter dosering) i uke 4
|
Før dosering, og på flere tidspunkt (opptil 7 timer etter dosering) i uke 4
|
|
|
Tid for å nå maksimal observerte plasmakonsentrasjon (Tmax) av Mitapivat
Tidsramme: Pre-dose, og ved flere tidspunkter (opptil 7 timer etter dose) i uke 4
|
Pre-dose, og ved flere tidspunkter (opptil 7 timer etter dose) i uke 4
|
|
|
Kohort 1: Prosentandel av kvinnelige deltakere med nyutviklede ovarielle cyster frem til uke 48
Tidsramme: Utgangspunkt, gjennom uke 48
|
Utgangspunkt, gjennom uke 48
|
|
|
Percentage of Participants Who Achieved TRR2 From Week 13 to Week 24
Tidsramme: Baseline, Week 13 through Week 24
|
TRR2 is defined as ≥50% reduction in transfused RBC volume (normalized by weight) from week 13 to week 24 compared with historical RBC transfusion volume (normalized by weight) and standardized to 12 weeks. |
Baseline, Week 13 through Week 24
|
|
Percentage of Participants Who Achieved TRR3 From Week 25 to Week 36
Tidsramme: Baseline, Week 25 through Week 36
|
TRR3 is defined as ≥50% reduction in transfused RBC volume (normalized by weight) from week 25 to week 36 compared with historical RBC transfusion volume (Normalized by Weight) and standardized to 12 weeks. |
Baseline, Week 25 through Week 36
|
|
Percentage of Participants Who Achieved TRR4 From Week 37 to Week 48
Tidsramme: Baseline, Week 37 through Week 48
|
TRR4 is defined as ≥50% reduction in transfused RBC volume (normalized by weight) from week 37 to week 48 compared with historical RBC transfusion volume (normalized by weight) and standardized to 12 weeks. |
Baseline, Week 37 through Week 48
|
|
Percentage of Participants Who Achieved TRR5 From Week 25 to Week 48
Tidsramme: Baseline, Week 25 through Week 48
|
TRR5 is defined as ≥50% reduction in transfused RBC volume (normalized by weight) from week 25 to week 48 compared with historical RBC transfusion volume (normalized by weight) and standardized to 24 weeks. |
Baseline, Week 25 through Week 48
|
|
Percentage of Participants Who Achieved Transfused Independence Through Week 48
Tidsramme: Baseline, through Week 48
|
Transfusion independence is defined as transfusion-free for greater than or equal to 8 consecutive weeks through Week 48. |
Baseline, through Week 48
|
Samarbeidspartnere og etterforskere
Sponsor
Sponsor
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Studiestart
Primær fullføring (Antatt)
Primær fullføring
Studiet fullført (Antatt)
Studiet fullført
Datoer for studieregistrering
Først innsendt
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Først lagt ut
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Sist oppdatering lagt ut
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
Andre studie-ID-numre
- AG348-C-029
- 2025-524707-71-00 (Ctis)
- 2025 (U.S. NIH-stipend/kontrakt)
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .